PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS

Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Main Authors: K. Simpson, N. Marlow, J. Shaw, А. V. Rudakova
Formáid: Artigo
Teanga:Inglês
Foilsithe: Paediatrician Publishers, LLC 2012-08-01
Sraith:Pediatričeskaâ Farmakologiâ
Ábhair:
juvenile idiopathic arthritis
adalimumab
cost-effectiveness analysis
Rochtain Ar Líne:https://www.pedpharma.ru/jour/article/view/302
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla